Navigation Links
Isis Pharmaceuticals Files Patent Infringement Suit Against Santaris Pharma
Date:9/23/2011

tellation of collaborative relationships with large and small companies advancing antisense drugs and the antisense technology platform," said B. Lynne Parshall, COO and CFO of Isis.  "A necessary component of our strategy is that we vigorously pursue infringement of our intellectual property.  The exemption from patent infringement for drug development was created to encourage rapid introduction of generic medicines.  We allege Santaris' activities are not protected by this exemption and that case law affirms our position."  

ABOUT ISIS PHARMACEUTICALS, INC.

Isis is exploiting its leadership position in antisense technology to discover and develop novel drugs for its product pipeline and for its partners.  Isis' broad pipeline consists of 24 drugs to treat a wide variety of diseases with an emphasis on cardiovascular, metabolic and severe and rare/neurodegenerative diseases, and cancer.  Isis' partner, Genzyme, plans to commercialize Isis' lead product, mipomersen, following regulatory approval, which is expected in 2012.  Isis' patents provide strong and extensive protection for its drugs and technology.  Additional information about Isis is available at www.isispharm.com.

ISIS PHARMACEUTICALS' FORWARD-LOOKING STATEMENT

This press release includes forward-looking statements regarding Isis' intellectual property position and its value in drug discovery and development.  Any statement describing Isis' goals, expectations, financial or other projections, intentions or beliefs, including the planned commercialization of mipomersen, is a forward-looking statement and should be considered an at-risk statement.  Such statements are subject to certain risks and uncertainties, particularly those inherent in the process of discovering, developing and commercializing drugs that are safe and effective for use as human therapeutics, and in the end
'/>"/>

SOURCE Isis Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
2. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
3. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
4. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
5. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
6. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
7. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
8. Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results
9. Access Pharmaceuticals Provides Update on Clinical Development Plan of ProLindac
10. Quark Pharmaceuticals Extends Research Agreement with State University of New York for Proprietary siRNA Compounds for Acute Hearing Loss
11. Acura Pharmaceuticals, Inc. Secures Financing to Fund Pivotal Phase III Clinical Trial for Lead Aversion(R) Technology Product Candidate
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/6/2015)... -- Cardinal Health today announced the completion of the ... generic pharmaceuticals, over-the-counter medications and related products to retail, ... Court Square Capital Partners. The $1.115 billion acquisition was ... Headquartered in Livonia, Mich. ... approximately $450 million in 2014. There are 450 employees ...
(Date:7/6/2015)... N.J. and FARMINGTON, Conn. ... Inc. (NYSE MKT: PTN), a biopharmaceutical company developing ... diseases with significant unmet medical need and commercial ... a private placement of Series E warrants to ... Series F warrants to purchase 2,191,781 shares of ...
(Date:7/6/2015)... 2015   Cepheid (Nasdaq: CPHD ) today ... 2015 second quarter ended June 30, 2015 on Thursday, ... The Company will host a management presentation ... 2015, to discuss the results.  To access the live ... at least 15 minutes before the scheduled start time ...
Breaking Medicine Technology:Cardinal Health Completes Acquisition Of The Harvard Drug Group For $1.115 Billion 2Cardinal Health Completes Acquisition Of The Harvard Drug Group For $1.115 Billion 3Palatin Technologies Completes $30 Million Financing 2Palatin Technologies Completes $30 Million Financing 3Palatin Technologies Completes $30 Million Financing 4Palatin Technologies Completes $30 Million Financing 5
... Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX ), ... human disease, announced today that results from the Phase ... with non-constipating irritable bowel syndrome (IBS) were published earlier ... journal Gastroenterology .  The issue also included an ...
... National Minority Quality Forum Issue Brief (Specialty Tiering: ... Puckrein and Gretchen Wartman examine specialty tiering, ... as a benefit-management tool to limit their financial exposure ... prescription drugs. The authors remind us that, the Institute ...
Cached Medicine Technology:Lexicon Announces Publication of Results From the Phase 2 Trial of LX1031 in Patients With Irritable Bowel Syndrome in Journal of Gastroenterology 2Lexicon Announces Publication of Results From the Phase 2 Trial of LX1031 in Patients With Irritable Bowel Syndrome in Journal of Gastroenterology 3Prescription-Drug Plans' Use of Specialty Tiers Promotes Inequalities 2
(Date:7/6/2015)... ... July 06, 2015 , ... ... southern California, has partnered with Woodbridge Walk-In Urgent Care to offer on-site health ... other serious medical conditions. Screenings are affordable and accurate and run about an ...
(Date:7/6/2015)... CA (PRWEB) , ... July 06, 2015 , ... Seedstock ... deliver the keynote address at the 4th Annual Seedstock Sustainable Agriculture Conference – “Innovation ... year’s conference , held at the University of California-San Diego, will explore solutions ...
(Date:7/6/2015)... ... July 06, 2015 , ... With ... has once again teamed up with Family Emergency Shelter Coalition (FESCO) and announced ... self-sufficiency. FESCO was created especially to provide emergency services and support for homeless ...
(Date:7/6/2015)... ... July 06, 2015 , ... In a split second, breaking a ... their risk of having a fracture through the bone health screenings conducted by American ... “We are participating because our residents need this information to remain independent and strong ...
(Date:7/6/2015)... ... July 06, 2015 , ... The School ... funds to support a three-year effort to reduce rates of diabetes and cardiovascular ... in partnership with the Morehouse School of Medicine’s Prevention Research Center and the ...
Breaking Medicine News(10 mins):Health News:Woodbridge Walk-In Offers Affordable Early Detection Health Screenings Through Longevity 2Health News:Seedstock Names Go Green Agriculture Founder and CEO as 2015 Sustainable Agriculture Conference Keynote Speaker 2Health News:Seedstock Names Go Green Agriculture Founder and CEO as 2015 Sustainable Agriculture Conference Keynote Speaker 3Health News:Seedstock Names Go Green Agriculture Founder and CEO as 2015 Sustainable Agriculture Conference Keynote Speaker 4Health News:Carlson & Associates Insurance Agency and Nonprofit Family Emergency Shelter Coalition (FESCO) Initiate New Charity Campaign in Alameda County, CA to Provide for Homeless 2Health News:Carlson & Associates Insurance Agency and Nonprofit Family Emergency Shelter Coalition (FESCO) Initiate New Charity Campaign in Alameda County, CA to Provide for Homeless 3Health News:National Bone Health Screening and Awareness Day 2Health News:Georgia State, Morehouse Partner To Tackle Diabetes, Heart Disease In Atlanta’s Minority Communities 2
... less effective in deep joint areas, study finds ... of hyaluronic acid is no more effective than a placebo ... , Hyaluronic acid (HA), a substance found in normal joint ... which lubricates and protects joints. The use of HA injections ...
... easier with some advance preparation , , FRIDAY, March 6 (HealthDay ... precious sleep when the clocks shift forward into daylight saving ... that you could lose a lot more if you don,t ... "There are more accidents on the road within two days ...
... United States has intervened in a whistleblower suit filed in ... (CHS) and three of its hospitals in New Mexico: Eastern ... Deming, and Alta Vista Regional Hospital in Las Vegas. ... the False Claims Act (FCA) by knowingly causing to be ...
... a statement of Esta Soler, President, Family Violence Prevention Fund:"Sadly, ... not unique -- women and girls in every community experience ... police report seems to suggest that this was an extremely ... is deeply disturbing. As with all dating and domestic ...
... VIEW, Calif., March 6 Alexza Pharmaceuticals, Inc. (Nasdaq: ... for its fiscal year ended December 31, 2008, on Tuesday, ... markets. The Company will host an investor conference call ... at 4:30 p.m. Eastern Time the same day. A ...
... may affect diaphragm, chest wall to decrease volume, study ... big around the middle can put the squeeze on ... than 120,000 people. , It was already known that ... women and greater than 40 inches for men) was ...
Cached Medicine News:Health News:Hip Osteoarthritis Therapy No Better Than Placebo 2Health News:Spring Forward? Plan Ahead 2Health News:United States Joins Suit Against Community Health Systems Inc. and Three of Its Hospitals in New Mexico 2Health News:Leading Domestic Violence Expert Comments on New Developments in the Rihanna/Chris Brown Case 2Health News:Alexza to Announce 2008 Financial Results and Update Its Clinical Pipeline on Tuesday, March 10, 2009 2Health News:Alexza to Announce 2008 Financial Results and Update Its Clinical Pipeline on Tuesday, March 10, 2009 3Health News:Belly Fat Puts the Pressure on Lungs 2
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products: